Form 8-K - Current report:
SEC Accession No. 0001628280-22-019889
Filing Date
2022-08-01
Accepted
2022-08-01 08:44:44
Documents
15
Period of Report
2022-07-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20220729.htm   iXBRL 8-K 40056
2 EX-99.1 ex-991apollo.htm EX-99.1 18593
6 GRAPHIC apollologoa.jpg GRAPHIC 16721
7 GRAPHIC avalo-logoxblk1a.jpg GRAPHIC 99614
  Complete submission text file 0001628280-22-019889.txt   360634

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20220729.xsd EX-101.SCH 1967
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20220729_lab.xml EX-101.LAB 24181
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20220729_pre.xml EX-101.PRE 12574
9 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20220729_htm.xml XML 10011
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 221122935
SIC: 2834 Pharmaceutical Preparations